Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Food Safety Reform Needs More Funding – Mike Taylor

This article was originally published in The Tan Sheet

Executive Summary

FDA will ask Congress to increase funding for implementing food safety reform, with particular interest in expanding the fees imposed on industry, Deputy Commissioner for Foods Mike Taylor says.

You may also be interested in...



Mandatory, Voluntary Recalls Distress Supplement Firms

Because a consent decree stipulated FDA could order Kabco Pharmaceuticals to recall products if the firm was found in violation, the enforcement did not emanate from the agency’s mandatory recall authority. Purity First Products, meanwhile, argues that FDA wrongly claimed the firm refused to conduct a recall.

Mandatory, Voluntary Recalls Distress Supplement Firms

Because a consent decree stipulated FDA could order Kabco Pharmaceuticals to recall products if the firm was found in violation, the enforcement did not emanate from the agency’s mandatory recall authority. Purity First Products, meanwhile, argues that FDA wrongly claimed the firm refused to conduct a recall.

Mandatory, Voluntary Recalls Distress Supplement Firms

Because a consent decree stipulated FDA could order Kabco Pharmaceuticals to recall products if the firm was found in violation, the enforcement did not emanate from the agency’s mandatory recall authority. Purity First Products, meanwhile, argues that FDA wrongly claimed the firm refused to conduct a recall.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel